Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Therapeutic Equivalence in Travelers' Diarrhea
NCT02920242Phase 3Terminated
- Sponsor
- Sandoz
- Start
- Dec 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifaximin in traveler's diarrhea (TD) (3 arms), sponsored by Sandoz. Primary endpoint: Clinical Cure Rate at Day 5. Started Dec 2016; status: terminated.
02
Drugs
rifaximin
03
Conditions
traveler's diarrhea (TD)
Beyond the preview
Go deeper on NCT02920242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920242.